20/20 Biolabs (AIDX) executive compensation, 2026 proxy

Jonathan Cohen, Chief Executive Officer, was paid $325,499 in 2025, down 59% from $796,257 the year before.

Filed
June 23, 2026
Annual meeting
August 18, 2026
Pay year
2025
Named executives
3
CEO total pay
$325,499-59% vs prior year
Cohen deferred amount
$49,994Accumulated deferred compensation
Zhou deferred amount
$73,327Accumulated deferred compensation
Lebowitz option awards
$62,0002025 grant-date fair value
401(k) match
3.5%Of first 6% contributed
2026 director cash fee
$40,000Effective April 1, 2026

How Cohen was paid

$325,499 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary77%All other compensation23%

Named executive officers

ExecutiveTotal
Jonathan CohenChief Executive Officer$325,499
Jiming ZhouChief Operating Officer$225,647
Michael LebowitzChief Scientific Officer$151,600

What changed and why

  • $325K$325,499 was Jonathan Cohen’s 2025 total compensation, compared with $796,257 in 2024.
  • $250K$250,000 was Jonathan Cohen’s 2025 salary, unchanged from 2024.
  • $75,499$75,499 was Jonathan Cohen’s 2025 all-other compensation, representing insurance benefits and 401(k) matches.
  • $62,000$62,000 was Michael Lebowitz’s 2025 option-award compensation; the other executives had no printed option-award amounts.
  • $49,994$49,994 of Jonathan Cohen’s compensation and $73,327 of Jiming Zhou’s compensation were deferred for fiscal years 2024 and 2025.
  • 3.5%3.5% of the first 6% of employee contributions is matched under the Company’s 401(k) plan.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.